Cover
Cover | Oct. 12, 2023 |
Cover [Abstract] | |
Entity Registrant Name | BIONEXUS GENE LAB CORP. |
Entity Central Index Key | 0001737523 |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | This Current Report on Form 8-K/A (this “Current Report”) amends the Current Report on Form 8-K filed by BioNexus Gene Lab Corp. (the “Company”) with the Securities and Exchange Commission on October 16, 2023 (the “Original Report”). It is being filed to update the Company’s disclosure under Item 5.02 of the Original Report to disclose the family relationship between the newly appointed Chief Executive Officer and director and the Company’s Chief Financial Officer (“CFO”). The Original Report otherwise remains unchanged. |
Entity Emerging Growth Company | true |
Document Period End Date | Oct. 12, 2023 |
Entity Ex Transition Period | false |
Entity File Number | 333-229399 |
Entity Incorporation State Country Code | WY |
Entity Tax Identification Number | 35-2604830 |
Entity Address Address Line 1 | Unit 2, Level 10, Tower B, Avenue 3 |
Entity Address Address Line 2 | The Vertical Business Suite II Bangar South |
Entity Address Address Line 3 | No. 8 Jalan Kerinchi |
Entity Address City Or Town | Kuala Lumpur |
Entity Address Postal Zip Code | 59200 |
City Area Code | 60 |
Local Phone Number | 1221-26512 |
Security 12b Title | Common Stock, no par value |
Trading Symbol | BGLC |
Security Exchange Name | NASDAQ |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Entity Address Country | MY |